Analysis: Rival treatments may help justify FDA gamble with Biogen Alzheimer's drug

Retrieved on: 2021-06-18 10:52:30

Tags for this article:

Click the tags to see associated articles and topics

Analysis: Rival treatments may help justify FDA gamble with Biogen Alzheimer's drug. View article details on hiswai:

Excerpt

But data expected much sooner on three drugs that work in a similar manner – Eli Lilly and Co's donanemab, Roche Holding AG's gantenerumab, and ...

Article found on: kfgo.com